Abstract:Introduction Obesity is a major risk factor for heart failure (HF); each one unit increase in BMI potentiates HF risk by 5% and 7% in men and women, respectively. In 2022, at Franciscan Health, Indianapolis, an Obesity Task Force was commissioned to tackle obesity by surveying existing local resources, develop clinical pathways, and institute a cardiology-driven obesity clinic for our outpatient HF patients. Hypothesis The cardiology-driven obesity clinic would lead to improved weight loss and subsequent improvement in the burden of HF symptoms, improved functional status, and reduction in HF hospitalizations. Methods Our multidisciplinary obesity task force including cardiology, endocrinology, bariatrics, primary care, nurses, health coaches and lifestyle program administrators developed an obesity HF algorithm. HF patients were identified in both the inpatient and outpatient setting and referred to a designated HF advanced practice provider as an outpatient. Requirements for referral included diagnosis of HF, BMI ≥30 and motivation to participate in lifestyle modifications. Lifestyle modifications included calorie/macronutrient tracking, appropriate exercise goals, educational materials on the DASH diet as well as videos on approaches to making dietary changes. Utilizing a shared decision-making process, patients were screened for candidacy of glucagon-like-peptide-1 (GLP-1) agonist. Each patient was also offered opportunity for referral to lifestyle programs that included health coaches. Patients started on the GLP-1 were seen every 4-6 weeks for dose titration and follow-up. Results Over a six-month time frame, 30 patients were seen in the obesity clinic (28 HFpEF, 2 HFrEF, 11 men, 19 women, mean age 58 yo, mean BMI 45 kg/m2, 8 with type II diabetes). Of the 30 patients, 12 initiated a GLP-1 agonist with another 10 attempted but declined by insurance. Two out of 12 achieved maximum GLP-1 dose. On average, patients have lost 10% of their starting weight with a range of 5-22%. All 30 patients were offered referral to lifestyle programs. Three patients started and stopped attending (none of them are currently on GLP-1), 8 are actively participating (5 are on GLP-1, 3 are lifestyle alone), and 19 declined referral. Of the patients who chose lifestyle alone, two have lost an average 4.4% starting body weight and one has gained weight. No patients have been admitted for HF exacerbation since being evaluated in the Obesity Clinic. Conclusions Treatment of obesity in the HF population represents a significant unmet medical need. Here we describe our approach to tacking this important risk factor by instituting a cardiology-driven obesity clinic for our outpatient HF patients. In the short time since implementation, we have seen meaningful reductions in weight in the majority of patients by combining a GLP-1 agent and lifestyle modifications. Unfortunately, GLP-1 insurance coverage remains a significant barrier, particularly for non-diabetic patients. Further follow-up will be critical to evaluate the impact our obesity clinic on sustainability of weight loss, impacts on functional status, as well as relevant HF metrics.

Obesity Medicine Intervention at an Academic Medical Center in a Resource-Limited Population Shows Promise

Impact Of An Embedded Obesity Clinic Within A Community Hospital Heart Failure Program

1678-P: Development and Implementation of a Comprehensive Shared Medical Appointment Model for Patients with Overweight and Obesity

Early weight loss outcomes from a newly established hospital-affiliated specialized obesity care delivery model in Central Florida

Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience

The long-term effectiveness of a lifestyle intervention in severely obese individuals

LEAD BY EXAMPLE: Evaluation of an NCCN and ASCO guideline-based virtual weight loss and healthy lifestyle intervention on providers and staff members at a comprehensive cancer center.

Approach to Obesity Treatment in Primary Care

Opportunities to optimize lifestyle interventions in combination with glucagon‐like peptide‐1‐based therapy

139-OR: An Obesity-centric Approach With and Without Antiobesity Medications Compared with the Usual-Care Approach to Management of Patients with Obesity and Type 2 Diabetes in an Employer Setting—A Pragmatic Randomized Controlled Trial (EMPOWER-T2D)

Management of Obesity: Office-Based Strategies

Teaching Medical Students to Help Patients Manage Their Weight: Outcomes of an Eight-School Randomized Controlled Trial

How Would You Manage This Patient With Obesity? Grand Rounds Discussion From Beth Israel Deaconess Medical Center

New insights into the treatment of obesity.

Obesity Management Solutions in Rural Communities

Attitudes, Perceptions, and Practices Among Endocrinologists Managing Obesity

Opportunities for General Internal Medicine to Promote Equity in Obesity Care

Effects of a 2-Year Primary Care Lifestyle Intervention on Cardiometabolic Risk Factors: A Cluster-Randomized Trial

Contemporary medical, device, and surgical therapies for obesity in adults

Implementing an evidence-based behavioral weight-loss program in community mental health centers: A randomized pilot study

Healthcare professionals' perceptions and management of obesity & knowledge of glucagon, GLP-1, GIP receptor agonists, and dual agonists